首页> 外文OA文献 >Investigation of localized delivery of diclofenac sodium from poly(D,L-lactic acid-co-glycolic acid)/ poly(ethylene glycol) scaffolds using an in vitro osteoblast inflammation model
【2h】

Investigation of localized delivery of diclofenac sodium from poly(D,L-lactic acid-co-glycolic acid)/ poly(ethylene glycol) scaffolds using an in vitro osteoblast inflammation model

机译:使用体外成骨细胞炎症模型研究从聚D,L-乳酸-乙醇酸/聚乙二醇支架中局部递送双氯芬酸钠

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nonunion fractures and large bone defects are significant targets for osteochondral tissue engineering strategies. A major hurdle in the use of these therapies is the foreign body response of the host. Herein, we report the development of a bone tissue engineering scaffold with the ability to release anti-inflammatory drugs, in the hope of evading this response. Porous, sintered scaffolds composed of poly(D,L-lactic acid-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) were prepared with and without the anti-inflammatory drug diclofenac sodium. Analysis of drug release over time demonstrated a profile suitable for the treatment of acute inflammation with ∼80% of drug released over the first 4 days and a subsequent release of around 0.2% per day. Effect of drug release was monitored using an in vitro osteoblast inflammation model, comprised of mouse primary calvarial osteoblasts stimulated with proinflammatory cytokines interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). Levels of inflammation were monitored by cell viability and cellular production of nitric oxide (NO) and prostaglandin E2 (PGE2). The osteoblast inflammation model revealed that proinflammatory cytokine addition to the medium reduced cell viability to 33%, but the release of diclofenac sodium from scaffolds inhibited this effect with a final cell viability of ∼70%. However, releasing diclofenac sodium at high concentrations had a toxic effect on the cells. Proinflammatory cytokine addition led to increased NO and PGE2 production; diclofenac-sodium-releasing scaffolds inhibited NO release by ∼64% and PGE2 production by ∼52%, when the scaffold was loaded with the optimal concentration of drug. These observations demonstrate the potential use of PLGA/PEG scaffolds for localized delivery of anti-inflammatory drugs in bone tissue engineering applications.
机译:骨不连骨折和大骨缺损是骨软骨组织工程策略的重要目标。使用这些疗法的主要障碍是宿主的异物反应。本文中,我们报道了具有释放抗炎药能力的骨组织工程支架的开发,以期逃避这种反应。在有和没有消炎药双氯芬酸钠的情况下,制备了由聚(D,L-乳酸-乙醇酸共聚物)(PLGA)和聚(乙二醇)(PEG)组成的多孔烧结支架。随时间推移对药物释放的分析表明,该药物适合于治疗急性炎症,前4天约80%的药物释放,随后每天约0.2%的释放。使用体外成骨细胞炎症模型监测药物释放的效果,该模型由促炎细胞因子白介素-1β(IL-1β),肿瘤坏死因子-α(TNF-α)和干扰素-γ(IFN)刺激的小鼠原发颅盖膜成骨细胞组成-γ)。通过细胞活力以及一氧化氮(NO)和前列腺素E2(PGE2)的细胞产生来监测炎症水平。成骨细胞炎症模型显示,促炎细胞因子添加到培养基中会使细胞活力降低至33%,但双氯芬酸钠从支架中的释放抑制了该作用,最终细胞活力约为70%。但是,以高浓度释放双氯芬酸钠对细胞具有毒性作用。促炎细胞因子的添加导致NO和PGE2产生增加;当该支架上装有最佳浓度的药物时,双氯芬酸钠释放支架可抑制NO释放约64%,PGE 2产生抑制约52%。这些观察结果证明了PLGA / PEG支架在骨组织工程应用中局部递送抗炎药的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号